Federal judges in Maryland, New Hampshire and Washington, DC, blocked the Trump administration from following through on threats to cut off funding to universities that engage in DEI efforts.
Sethuraman Panchanathan, director of the National Science Foundation, will resign from the position 16 months before the scheduled end of his six-year term.
W. Kimryn Rathmell, former director of the NCI, has accepted the role as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
William N. Hait was named as chief scientific advisor to the American Association for Cancer Research.
The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to FDA’s Richard Pazdur during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago.
Lisa MontezStephen WhisnantLisa Montez and Stephen Whisnant were appointed to the National Coalition for Cancer Survivorship board of directors. Montez and Whisnant are cancer survivors who bring exceptional experience in philanthropy, nonprofit leadership, and a deep commitment to improving the lives of others.
Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.
The American Association for Cancer Research-Novocure Career Development Award for Cancer Research represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.
